CoChat

Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2)

Wägner, A.M., Miranda-Calderín, G., Ugarte-Lopetegui, M.A., Marrero-Santiago, H., Suárez-Castellano, L., López-Madrazo, M.J., Alberiche-Ruano, M.P., Abselam Ahmed, N., Alemán, C., Castellot-Martín, A., Díez del Pino, A., Nóvoa-Mogollón, F.J. · 2019 · Diabetes & Metabolism
Cited by 24

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

AIMS To assess the effect of the GLP-1 analogue liraglutide on measures of cardiac function and physical performance in patients with type 2 diabetes (T2D). METHODS In this phase-IV randomized double-blind placebo-controlled parallel-group clinical trial at a tertiary hospital, T2D patients with HbA1c levels of 7-10% with oral agents and/or intermediate-/long-acting insulin were allocated (computer-generated randomization, ratio 1:1) to either liraglutide 1.8 mg/day or a placebo for 6 months. The primary endpoint was maximum oxygen consumption (VO2max) during cycle ergometry, while other procedures included a 6-min walk test, echocardiography, anthropometry and blood tests. Safety endpoints were also monitored, and an intention-to-treat analysis was performed. RESULTS A total of 24 patients (15 women) aged 52 (11.7) years, with diabetes duration of 8.7 (5.8) years, BMI 34.98 (6.2) kg/m2 and HbA1c 8.2% (0.68%), were randomized to liraglutide 1.8 mg daily or placebo. There were no differences in VO2max [17.98 (4.8) vs. 15.90 (4.96) mL/kg/min; P > 0.10], VE/VCO2 slope [30.18 (4.8) vs. 32 (4.49)], left ventricular ejection fraction or 6-min walk test [530.7 (86) vs. 503.9 (84) m] at 6 months. HbA1c was lower (6.7% vs. 7.7%; P = 0.005), with a trend towards lower maximum systolic blood pressure during ergometry [171.7 (24.4) vs. 192.5 (25.6); P = 0.052] in the liraglutide group at the end of the study. There were no severe adverse events. CONCLUSION In this trial, liraglutide improved glycaemic control in T2D, but had no significant effects on either physical performance or myocardial function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.diabet.2018.08.010

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 15

  1. Bethel, 2018, Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis, Lancet Diabetes Endocrinol, 6, 105, 10.1016/S2213-8587(17)30412-6 · DOI · Paper page
  2. Sokos, 2007, Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting, Am J Cardiol, 100, 824, 10.1016/j.amjcard.2007.05.022 · DOI · Paper page
  3. Read, 2011, A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans, Circ Cardiovasc Interv, 4, 266, 10.1161/CIRCINTERVENTIONS.110.960476 · DOI · Paper page
  4. Read, 2012, Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease, Heart, 98, 408, 10.1136/hrt.2010.219345 · DOI · Paper page
  5. Lønborg, 2012, Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction, Eur Heart J, 33, 1491, 10.1093/eurheartj/ehr309 · DOI · Paper page
  6. Wägner, 2016, Effect of liraglutide on physical performance in type 2 diabetes (LIPER2): a randomised, double-blind, controlled trial, Contemp Clin Trials Commun, 4, 46, 10.1016/j.conctc.2016.06.007 · DOI
  7. Guazzi, 2016, 2016 Focused Update: Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations, Circulation, 133, e694, 10.1161/CIR.0000000000000406 · DOI · Paper page
  8. Villa-Caballero, 2007, Hemodynamic and oxidative stress profile after exercise in type 2 diabetes, Diabetes Res Clin Pract, 75, 285, 10.1016/j.diabres.2006.07.011 · DOI
  9. Lang, 2006, Euro J Echocardiogr, 7, 79, 10.1016/j.euje.2005.12.014 · DOI · Paper page
  10. Scheen, 2017, GLP-1 receptor agonists and heart failure in diabetes, Diabetes Metab, 43, 13, 10.1016/S1262-3636(17)30068-X · DOI
  11. Pocock, 2016, The primary outcome fails-what next?, N Engl J Med, 375, 861, 10.1056/NEJMra1510064 · DOI · Paper page
  12. Nesbitt, 2009, Strain imaging in echocardiography: methods and clinical applications, Int J Cardiovasc Imaging, 25, 9, 10.1007/s10554-008-9414-1 · DOI · Paper page
  13. Htike, 2016, Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study), Cardiovasc Diabetol, 15, 102, 10.1186/s12933-016-0421-6 · DOI
  14. Jørgensen, 2017, Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: a randomized double-blind placebo-controlled clinical trial, Diabetes Obes Metab, 19, 1040, 10.1111/dom.12900 · DOI · Paper page
  15. Arturi, 2017, Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure, Endocrine, 57, 464, 10.1007/s12020-016-1166-4 · DOI

Cited by

See all 24

Metadata

Authors
Wägner, A. M., Miranda-Calderín, G., Ugarte-Lopetegui, M. A., Marrero-Santiago, H., Suárez-Castellano, L., López-Madrazo, M. J., Alberiche-Ruano, M. P., Abselam Ahmed, N., Alemán, C., Castellot-Martín, A., Díez del Pino, A., & Nóvoa-Mogollón, F. J.
Venue
Diabetes & Metabolism
Publisher
Elsevier BV
Published
2019-06
Volume
45
Issue
3
Pages
268-275
ISSN
1262-3636 (ISSN-L)
OpenAlex
W2891135391
Cited by
24
References
10
FWCI
1.36
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
Novo Nordisk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2). https://app.cochat.ai/papers/10.1016/j.diabet.2018.08.010
The paper
Wägner, A. M., Miranda-Calderín, G., Ugarte-Lopetegui, M. A., Marrero-Santiago, H., Suárez-Castellano, L., López-Madrazo, M. J., Alberiche-Ruano, M. P., Abselam Ahmed, N., Alemán, C., Castellot-Martín, A., Díez del Pino, A., & Nóvoa-Mogollón, F. J. (2019). Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2). Diabetes & Metabolism. https://doi.org/10.1016/j.diabet.2018.08.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.